Contact Us
.
Whitepaper

As Pricing Programs Evolve, the Time Is Now for Gross-to-Net Intelligence

Fill out form to download

The drug pricing landscape is becoming more complex. As 340B continues to grow and programs like Maximum Fair Price (MFP) introduce new requirements, manufacturers face increasing pressure to understand where programs overlap and how they impact gross-to-net (GTN).
Claims-level data can provide the visibility needed to navigate this complexity, reduce duplicate discounts, and better protect revenue.

Download the whitepaper to learn how manufacturers can:

  • Improve visibility across 340B and other drug pricing programs
  • Identify and reduce duplicate discounts
  • Strengthen compliance with claims-level validation
  • Connect claims data with broader GTN intelligence
  • Prepare for evolving 340B and MFP requirements

See how Model N and Truzo can help manufacturers move beyond fragmented program management toward a more connected, transparent view of GTN.